Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings

Ítems similars

• Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications
  per: Koshimichi, Hiroki, et al.
  Publicat: (2020)
• Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
  per: Hirotsu, Nobuo, et al.
  Publicat: (2020)
• 1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications
  per: Koshimichi, Hiroki, et al.
  Publicat: (2019)
• Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
  per: Yokoyama, Takato, et al.
  Publicat: (2020)
• Population Pharmacokinetics of Peramivir in Healthy Volunteers and Influenza Patients
  per: Matsuo, Yumiko, et al.
  Publicat: (2015)